Royalty Pharma plc (RPRX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $380.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.58B; Long-term DebtUSD $8.96B; Debt Instrument, Unamortized DiscountUSD $218.11M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $380.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.58B; Long-term DebtUSD $8.96B; Debt Instrument, Unamortized DiscountUSD $223.56M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $380.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.57B; Long-term DebtUSD $8.95B; Debt Instrument, Unamortized DiscountUSD $229.08M.
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $380.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.57B; Long-term DebtUSD $8.95B; Debt Instrument, Unamortized DiscountUSD $234.26M.
Royalty Pharma plc Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|
| 2026-06-30 | $380.00M | $8.58B | $8.96B | $218.11M | (m) |
| 2026-03-31 | $380.00M | $8.58B | $8.96B | $223.56M | (m) |
| 2025-12-31 | $380.00M | $8.57B | $8.95B | $229.08M | (m) |
| 2025-09-30 | $380.00M | $8.57B | $8.95B | $234.26M | (m) |
| 2025-06-30 | $999.44M | $7.00B | $8.00B | $177.50M | (m) |
| 2025-03-31 | $998.61M | $6.62B | $7.62B | $182.55M | (m) |
| 2024-12-31 | $997.77M | $6.61B | $7.61B | $187.57M | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | $187.57M |
| 2024-09-30 | $996.94M | $6.61B | $7.61B | $192.62M | (m) |
| 2024-06-30 | $0.00 | $7.60B | $7.60B | $197.98M | (m) |
| 2024-03-31 | $0.00 | $6.14B | $6.14B | $160.62M | (m) |
| 2023-12-31 | $0.00 | $6.14B | $6.14B | (m) | $164.72M |
| 2023-12-31 | (m) | (m) | (m) | $164.72M | (m) |
| 2023-09-30 | $0.00 | $6.13B | $6.13B | $168.81M | (m) |
| 2023-06-30 | $999.37M | $6.13B | $7.13B | $173.56M | (m) |
| 2023-03-31 | $998.44M | $6.12B | $7.12B | $178.62M | (m) |
| 2022-12-31 | $997.51M | $6.12B | $7.12B | (m) | $183.68M |
| 2022-12-31 | (m) | (m) | (m) | $183.68M | (m) |
| 2022-09-30 | $996.58M | $6.11B | $7.11B | $188.74M | (m) |
| 2022-06-30 | $0.00 | $7.11B | $7.11B | $193.80M | (m) |
| 2022-03-31 | $0.00 | $7.10B | $7.10B | $198.86M | (m) |
| 2021-12-31 | $0.00 | $7.10B | $7.10B | (m) | $203.93M |
| 2021-12-31 | (m) | (m) | (m) | $203.93M | (m) |
| 2021-09-30 | $0.00 | $7.09B | $7.09B | $209.33M | (m) |
| 2021-06-30 | $0.00 | $5.83B | $5.83B | $174.44M | (m) |
| 2021-03-31 | $0.00 | $5.82B | $5.82B | $178.93M | (m) |
| 2020-12-31 | $0.00 | $5.82B | $5.82B | (m) | $183.42M |
| 2020-12-31 | (m) | (m) | (m) | $183.42M | (m) |
| 2020-09-30 | $0.00 | $5.81B | (m) | (m) | (m) |
| 2020-06-30 | $182.23M | $5.73B | (m) | (m) | (m) |
| 2019-12-31 | $281.98M | $5.96B | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |